Hederagenin improves renal fibrosis in diabetic nephropathy by regulating Smad3/NOX4/SLC7A11 signaling-mediated tubular cell ferroptosis
International Immunopharmacology · 2024-06 · 135 · 112303
DOI: 10.1016/j.intimp.2024.112303 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-06. Verfasst von Jian Jia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China. Hauptthemen laut MEDLINE: Ferroptosis, Smad3 Protein, Diabetic Nephropathies, NADPH Oxidase 4. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a common complication of diabetes, characterized by renal fibrosis and poor patient prognosis. Hederagenin (HDG) has shown promising improvement in chronic kidney disease (CKD) kidney fibrosis, but its mechanism in DN-induced kidney fibrosis remains unclear. In this study, a model of diabetic nephropathy (DN) in mice was induced by intraperitoneal injection of streptozocin (50 mg/kg), while in vitro, high glucose (25 mM) was used to induce HK2 cell damage, simulating tubular injury in DN kidneys. The improvement of HDG treatment intervention was evaluated by observing changes in renal function, pathological structural damage, and the expression of fibrosis-related proteins in renal tubular cells. The results demonstrate that HDG intervention alleviates renal dysfunction and pathological damage in DN mice, accompanied by reduced expression of fibrotic markers α-smooth muscle actin (α-SMA), fibronectin (FN) and Collagen-I. Mechanistically, this study found that HDG can inhibit ferroptosis and fibrosis induced by the ferroptosis inducer Erastin (1 μM) in renal tubular cells. Phosphorylation of Smad3 promotes ferroptosis in renal tubular cells. After using its specific inhibitor SIS3 (4 μM), the expression of downstream target protein NADPH oxidase 4 (NOX4) significantly decreases, while the level of glutathione peroxidase 4 (GPX4) is notably restored, mitigating ferroptosis. Smad3 overexpression attenuates the therapeutic effect of HDG on tubular cell fibrosis induced by high glucose. These results demonstrate HDG inhibits Smad3 phosphorylation, thereby reducing the expression of NOX4 and enhancing the expression of GPX4, ultimately attenuating ferroptosis induced renal fibrosis. These findings suggest that HDG offer therapeutic potential for DN renal fibrosis by targeting Smad3-mediated ferroptosis in renal tubular cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China.
- Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing 101300, China.
- Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing 101300, China. Electronic address: liupeng1@xnykdhbszyy.onexmail.com.
- Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou 646000, China. Electronic address: wangli120@swmu.edu.cn.
Zitieren
APA
Jia, J., Tan, R., Xu, L., Wang, H., Li, J., Su, H., Zhong, X., Liu, P., & Wang, L. (2024). Hederagenin improves renal fibrosis in diabetic nephropathy by regulating Smad3/NOX4/SLC7A11 signaling-mediated tubular cell ferroptosis. International Immunopharmacology, 135, 112303. https://doi.org/10.1016/j.intimp.2024.112303
Vancouver
Jia J, Tan R, Xu L, Wang H, Li J, Su H, et al. Hederagenin improves renal fibrosis in diabetic nephropathy by regulating Smad3/NOX4/SLC7A11 signaling-mediated tubular cell ferroptosis. International Immunopharmacology. 2024;135:112303. doi:10.1016/j.intimp.2024.112303
BibTeX
@article{Jia2024,
author = {Jia, Jian and Tan, Ruizhi and Xu, Linghui and Wang, Honglian and Li, Jianchun and Su, Hongwei and Zhong, Xia and Liu, Peng and Wang, Li},
title = {Hederagenin improves renal fibrosis in diabetic nephropathy by regulating Smad3/NOX4/SLC7A11 signaling-mediated tubular cell ferroptosis},
journal = {International Immunopharmacology},
year = {2024},
volume = {135},
pages = {112303},
doi = {10.1016/j.intimp.2024.112303}
}
EUVIMED